MET and breast cancer: Indeed, c-Met immunostaining in four breast cancer samples (Additional file, Table 2) revealed a strong positivity in two samples orgining from patients displaying a recurrent pathology after 4 and 7 months from the first fat graft, a weak/moderate staining was seen in two samples origining from patients without signs of recurrence after 6 and 22 months from the first fat graft (Figure 8C).